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PhenoStacks: Cross-Sectional Cohort Phenotype 
Comparison Visualizations 
Michael Glueck, Alina Gvozdik, Fanny Chevalier, Azam Khan, Michael Brudno, Daniel Wigdor 
Abstract—Cross-sectional phenotype studies are used by genetics researchers to better understand how phenotypes vary across 
patients with genetic diseases, both within and between cohorts. Analyses within cohorts identify patterns between phenotypes and 
patients (e.g., co-occurrence) and isolate special cases (e.g., potential outliers). Comparing the variation of phenotypes between two 
cohorts can help distinguish how different factors affect disease manifestation (e.g., causal genes, age of onset, etc.). PhenoStacks 
is a novel visual analytics tool that supports the exploration of phenotype variation within and between cross-sectional patient cohorts. 
By leveraging the semantic hierarchy of the Human Phenotype Ontology, phenotypes are presented in context, can be grouped and 
clustered, and are summarized via overviews to support the exploration of phenotype distributions. The design of PhenoStacks was 
motivated by formative interviews with genetics researchers: we distil high-level tasks, present an algorithm for simplifying ontology 
topologies for visualization, and report the results of a deployment evaluation with four expert genetics researchers. The results 
suggest that PhenoStacks can help identify phenotype patterns, investigate data quality issues, and inform data collection design. 
Index Terms—Cross-sectional cohort analysis, Phenotypes, Human Phenotype Ontology (HPO)
 
1 INTRODUCTION 
The insights we garner by deepening our understanding of human 
genetics can improve general medical practice, from better predicting 
the side effects of medical interventions [14] to guiding new 
approaches to treat everyday diseases [1]. As studying rare genetic 
diseases can lead to broad insights into human genetics, genetics and 
genomics scientists, as well as clinical geneticists, continue to unravel 
the complex interactions between genes, environment, and visual 
manifestations (i.e., phenotypes) [14]. 
Phenotypes are observable and measureable patient traits primarily 
caused by genetic variation. They describe abnormalities with respect 
to morphology (i.e., structural features such as having a broad thumb 
or low-set ears), physiology (i.e., functional features such as cognitive 
impairment or seizures), or behavior (e.g., depression or impulsivity). 
Genetics and medical researchers study the spectrum of phenotypic 
abnormalities associated with rare genetic diseases to garner insights 
into the multitude of factors affecting disease characteristics and 
manifestations. For example, the more comprehensive patient 
phenotype reports, the higher the chances of discovering the gene 
variants responsible for a given disease [13]. 
Although phenotypes are powerful indicators of disease and have 
a long history of use in diagnostic medicine, formative interviews with 
genetics researchers indicated that there is a lack of standardized 
workflows and systematic approaches to phenotype data analysis. 
Individual research groups typically collect phenotype data using self-
designed instruments and protocols, manage internal databases, and 
conduct analyses using a combination of custom scripts, spreadsheets, 
and statistical packages. Unlike gene-oriented analyses (e.g., [37], 
[40]), dedicated tools for phenotype analyses do not exist. This is in 
large part due to use of natural language to describe phenotypes within 
electronic health records (EHRs) or in published case reports. Such 
language results in unstructured phenotype data. While access to 
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Fig. 1. PhenoStacks employs an observations plot (D) to reveal the distribution of phenotypes (rows) across patients (columns) in a 
cohort, which can be sorted by patient or phenotype attributes. Similar phenotypes can be grouped based on the Human Phenotype 
Ontology (B,C). Radial hierarchies (A) summarize global patterns. Views are linked, e.g., search results (E) are highlighted (A,C,D). 
 
 
centralized disease registries is growing, phenotype data collected by 
different investigators and institutions varies widely depending on 
collection protocols, diagnostic methodologies, and resource 
constraints, as well as measurement subjectivity and investigator 
diagnostic interests and priorities. Many notations, abbreviations, and 
synonymous terms have evolved [32] and are reported at different 
granularities of detail [24]. These factors can introduce uncertainty 
regarding the actual observations of a clinician when comparing 
published results [33] and complicates computational analysis. 
Structured approaches to phenotype data aim to address these 
issues of consistency, completeness, granularity, and computability. 
The Human Phenotype Ontology (HPO) [18] is the first ontology for 
phenotypes; an on-going initiative to standardize terminology and add 
structure by defining relationships between phenotypes (i.e., semantic, 
logical, hierarchical). The HPO also facilitates interoperability with 
external disease databases that link genes, phenotypes, and diseases 
(e.g., OMIM, OrphaNet) [34]. Leveraging the HPO structure and 
external resource integration enables computation on phenotypes that 
is not possible using current nomenclatures alone (e.g., ICD-10). For 
example, the similarity of patients with non-overlapping phenotype 
observations can be calculated and concepts like diagnostic 
significance can be quantified [19]. Despite the popularity of this 
resource in the genetics community, very few tools are available to 
help scientists visualize, analyze, and compute on cohorts of patients 
described using terms from the HPO. 
This work contributes PhenoStacks, a visual analysis tool that 
enables genetics scientists and researchers to explore phenotypic 
variation in cross-sectional cohorts of patients with a rare genetic 
disease. Interviews with domain experts identified a series of high-
level cross-sectional cohort analysis tasks that guided the development 
and design of PhenoStacks. Within PhenoStacks, potential metrics of 
interest (e.g., frequency, similarities, entropy) are automatically 
extracted and encoded in summary charts that guide a goal-oriented 
visual exploration of detailed patient phenotype plots. The tool can be 
used to investigate the distribution of patient phenotypes within a 
single cohort or compare and contrast similarities and differences of 
phenotype distribution across patients between cohorts. In addition, 
we contribute a novel algorithm for simplifying ontology topology 
visualization and visualization concepts that can be applied to other 
domains where instances of taxonomies or ontologies are analyzed. 
PhenoStacks is available as an open source project at phenostacks.org. 
2 BACKGROUND AND RELATED WORK 
Rare genetic diseases afflict an estimated 350 million people world-
wide, with approximately 30 million patients in the US alone [10]. 
While there are more than 8,000 named rare genetic diseases, many 
more are yet to be discovered or classified [32]. Those that have been 
identified are difficult to diagnose, as their low occurrence means 
clinicians only encounter a handful of cases over their career. On 
average, these patients will be misdiagnosed twice, interact with four 
clinical specialists, and wait seven years for a correct diagnosis [39]. 
Clinical specialists and genetics researchers both contribute to the 
advanced study of rare genetic diseases in a virtuous cycle. Through 
direct interactions with patients, clinicians are the primary collectors 
of the data used by researchers to deepen our understanding of human 
genetics. Research results are, in turn, applied to developing more 
robust diagnostic tests. These advances are critical to improving 
patient quality of life by reducing unnecessary diagnostic testing and 
mitigating the uncertainty of a diagnosis. Ultimately, expanding our 
understanding of the underlying genetic factors affecting diseases is 
key to realizing the vision of personalized healthcare promised by 
analysis of patient genomes [13]. 
Given the importance of phenotypes, both specialists and genetics 
researchers stand to benefit from advanced tools that promote the use 
of consistent phenotype terminology and facilitate comprehensive 
phenotyping. This is precisely a scenario where visual analysis tools 
can excel: combining the strengths of perception and computation into 
an interactive process that extracts knowledge from data [17]. 
2.1 Role of Phenotypes 
When studying rare diseases, patient phenotypes are the best method 
to describe symptoms and manifestations, and to identify similar cases 
[1][4][13][30][32]. Generally, complete and granular phenotypes are 
necessary to differentiate between disease subtypes and to guide 
diagnostic tests to confirm a specific disorder using advanced 
modalities (e.g., genetic testing). Due to resource constraints, current 
technologies render it impractical to compile a complete and granular 
workup of every phenotype for each patient (i.e., deep phenotyping 
[32]). The onus thus remains on clinicians to prioritize diagnostic tests 
and compile consistent and detailed phenotype reports. The reality, 
however, is that researchers would benefit from more detailed 
phenotyping than is typically necessary for diagnosis. 
Although research initiatives are exploring computational 
approaches to infer phenotypes from EHRs (e.g., PheKB) and sharing 
patient data to improve the accuracy of these methods (e.g., PCORnet, 
NIH Collaboratory), EHR coding schemes (e.g., MeSH, ICD-10, 
SNOMED CT) are inconsistent and incomplete in their coverage of 
phenotype terms [41][44], and lack the granularity required to study 
rare diseases [41]. Similarly, extracting clinical information from 
research articles (e.g., PubMed) remains a challenging area of research 
[12]. The HPO complements these data mining efforts, since mapping 
extracted data to HPO terms provides access to existing computational 
approaches. The HPO is already being used successfully in novel tools 
that provide systematic methods of entering complete and granular 
patient phenotype data (e.g., PhenoTips [9]) and that facilitate 
matching patients with undiagnosed rare diseases based on phenotype 
similarity (e.g., PhenomeCentral [4], MatchMaker Exchange [30]).  
2.2 Visualizations of Genetics Data 
Numerous visualization tools have been developed to assist 
geneticists. Most of these systems visualize genotype data using three 
classical visualization techniques (see Schroeder et al. [35] for a 
review). Heatmaps are commonly employed to represent genomic 
values in a compact color-coded matrix (e.g., cBio [6]) or in a circular 
view (e.g., CircleMap [42]). Space-filling layouts based on genome 
coordinates have been applied to genome browsers (e.g., Savant 2 [7]) 
and genome comparison visualization tools (e.g., Circos [21], Mizbee 
[26]). Finally, network representations have been used to explore large 
biological networks (e.g., Cytoscape [38]) or gene pathways (e.g., 
VisANT [15]). Specific visualization challenges have also been 
addressed, such as introducing a visual language for depicting genome 
assemblies (e.g., AbyssExplorer [27]). 
Fewer visualization tools have focused on comparing phenotypes; 
most existing systems are designed to better understand the causality 
of gene variation on phenotypes. Representations, such as Manhattan 
plots, have been used to reveal complex associations between genes, 
proteins, and phenotypes (e.g., Arena3D [36], PheWAS-View [28]). 
The HPO is rarely used for visualization and was only recently first 
employed in PhenoBlocks [11]. In this prior work, we used the HPO 
to visualize phenotypes in clinical diagnosis settings, supporting the 
pairwise comparison of patient phenotypes using explicit encoding. In 
the present work, we turn our focus to genetics researchers conducting 
cross-sectional cohort studies, where the distribution of phenotypes is 
compared across many patients. 
2.3 Visualizations of Cohorts 
Supporting analysis of patient cohorts has been addressed in the 
visualization literature (see Rind et al. [31] for a review), with a focus 
on longitudinal cohorts in clinical settings. Recent works investigated 
analyzing temporal constraints of cohort membership (i.e., COQUITO 
[20]), exploring temporal events within a cohort (i.e., CAVA [45]), 
and comparing temporal events between cohorts (i.e., CoCo [25]). 
Although our work focuses on cross-sectional cohort analyses, we 
share the high-level goals of comparing patients within and between 
cohorts to identify patterns of cohort membership in an exploratory 
context, however we focus on phenotypes, instead of temporal events. 
 
 
2.4 Visualizations of Ontologies 
Ontologies are used to capture the conceptual structure of a domain. 
Using graphs, the relationships between entities (e.g., causation, 
inheritance) can be encoded and establish a common ground for 
discussion and knowledge sharing. Many visualization tools have 
represented ontologies [16][22] and bio-ontologies [43]. Carpendale 
et al. [5] review bio-ontologies from the perspective of visualization, 
identifying challenges and research opportunities, such as annotating 
data and visualizing annotated content. Katifori et al. [16] surveyed a 
variety of visualization approaches in the literature, identifying 
indented lists and space-filling hierarchical layouts (e.g., icicle, radial) 
as popular and effective approaches. Katifori et al. note several 
problems remain poorly addressed in most existing systems, including 
clutter reduction (topologies can be complex), structure 
(visualizations fail to convey overall structure), scalability (large 
ontologies are not handled well) and inspection (querying ontologies). 
Clutter reduction and structure are addressed in PhenoStacks. 
3 CROSS-SECTIONAL COHORT ANALYSIS 
Cohort studies are frequently used in medicine, in both longitudinal 
and cross-sectional designs. Longitudinal analyses are often used in 
clinical studies, such as evaluating the effectiveness of treatments 
[20][25][45]. In contrast, cross-sectional cohort studies are typically 
descriptive, such as quantifying features of a patient population (e.g., 
the prevalence of a specific symptom of a disease) or evaluating 
metrics to differentiate subpopulations (e.g., whether a biochemical 
marker correlates to disease severity). In tandem, cross-sectional and 
longitudinal study designs provide complementary perspectives on 
patient data, to first identify disease subtypes and causal factors, and 
then study their correlations to disease progression and treatments. 
To better understand how cross-sectional cohort analysis is used in 
genetics research, semi-structured interviews were conducted with six 
domain experts: four experienced genetics researchers (MD/PhD; 6-
12 years of experience), one research manager (MSc; 8 years of 
experience), and a research fellow (PhD; 4 years of experience). Their 
specializations spanned a range of rare genetic diseases, including 
neuromuscular, metabolic, and inflammatory bowel diseases. We first 
report on barriers, goals, and types of analyses and then relate these to 
an abstract task typology from the visualization literature that can 
guide the design of tools for medical cross-sectional cohort analysis. 
3.1 Barriers and Pain Points 
Researchers described that published results of cross-sectional cohort 
studies often report only descriptive statistics of phenotype occurrence 
(i.e., frequency, mean, variance). Although this provides a sense of the 
average patient in a cohort, it masks the actual distribution and co-
occurrences of phenotypes for each patient. Preserving the granularity 
of phenotype reporting and standardized naming of phenotypes would 
improve the ability to reuse the results of these studies. 
In any research center, there are very few patients for any given 
rare disease. The researchers we interviewed explained that detailed 
phenotypes of diagnosed cases were once disseminated within the 
scientific community through case reports of single patients, but this 
practice is in decline with increasing availability of large curated 
disease registries. Sharing patient phenotype data across departments, 
institutions, and countries is thus easier, and studies can now include 
larger cohorts (i.e., 10s to 100s of patients). With more data, however, 
data quality is an increasing concern (i.e., completeness, consistency, 
and granularity). Although deep phenotyping is the ideal scenario, the 
practice is prohibitive due to its time-consuming nature, required 
expertise in the disease, and lack of available resources. Reaching 
consensus on what phenotypes should be collected and reported is a 
slow process. In particular, when faced with patients with rare or 
undiagnosed diseases, the researchers noted it can be equally difficult 
to decide at what granularity to report phenotypes. Another concern 
was efficiently integrating data across multiple databases as the size 
of data continues to grow. We determined that structured phenotype 
data can begin to address these issues. 
3.2 Analysis Goals 
In genetics research, cross-sectional cohort analyses may focus within 
a cohort (i.e., patterns across patients), or between cohorts (i.e., 
patterns between cohorts). Here, we summarize the common tasks 
described in our interviews. 
3.2.1 Within-Cohort Analysis 
Within-cohort analyses are useful to discover emergent patterns 
(W1) of phenotypes between patients (e.g., frequency, distribution, 
co-occurrence). The results provide insight into the scope of a disease 
(e.g., localized vs systemic) which can differentiate symptoms from 
unrelated abnormalities. 
Comparing phenotypes between patients in a cohort can identify 
outlier patients/phenotypes (W2). Phenotype presentations that are 
atypical of the cohort, or very rare phenotypes, can indicate special 
cases where the patient may not respond to existing therapies or there 
is potential to better classify disease subtypes. 
Subcohort discovery (W3) can help develop more effective 
diagnostic tests and treatments by identifying new disease subtypes. 
This involves discovering groups of patients within a disease cohort 
that can be differentiated from each other based on measurable 
attributes (e.g., phenotypes, causal gene variants, biochemical 
markers). 
Within-cohort analyses can also help audit data quality (W4), 
ensuring that phenotype data collection is consistent and complete. 
For example, is the granularity sufficiently detailed to differentiate 
subcohorts? This is particularly important for larger studies that 
involve multiple investigators, institutions, and disease registries. 
These analyses (W1-W4) are typically informal and exploratory 
undertakings. Hypotheses are later tested using statistical approaches. 
Such results can be used to quantify disease prevalence (W5) within 
subpopulations (e.g., geographic, demographics, ethnicity). Studying 
these specific incident rates can identify potential environmental 
influences on diseases or groups requiring special consideration. 
The results of these analyses often lead to improved disease 
characterization (W6) based on identified patterns. The application 
of these characterizations in clinical settings can set expectations 
about disease severity, clinical prognosis, and the effectiveness of 
available treatments. This can help doctors to better plan interventions 
and to explain a disease to patients and families. 
3.2.2 Between-Cohort Analysis 
Between-cohort analyses enable comparison of patterns across 
disease subtypes (B1). For example, age of disease onset is a factor 
of frequent interest. Patients who exhibit symptoms of a disease at 
younger ages more typically have congenital forms (i.e., inherited), 
while patients who develop the disorder later in life may have been 
exposed to environmental triggers. In addition, by comparing patients 
with less- and more-severe forms of a disease, more general patterns 
can be isolated. While outlier phenotypes and special patient cases are 
of significant research interest, very consistent and general patterns 
are most applicable to developing useful treatments. 
Between-cohort analyses are important to validate data quality 
(B2). When collecting new patient data for a cohort study, it is 
important to compare to existing registries to ensure the local cohort 
is representative. When publishing results, it is critical to describe 
salient similarities and differences to previously published results 
(e.g., case reports). When compiling patient data across registries, it is 
important to compare cohorts to evaluate whether it is appropriate to 
assimilate them. These comparisons can also be used to evaluate the 
observational methodologies of registries. 
Results of between-cohort analyses can further be used to inform 
clinical practice (B3). Subpopulations may be differentiated by non-
clinical attributes (e.g., ethnicity) to determine whether some 
subpopulations require additional consideration (e.g., more frequent 
screening). Since the presentation of phenotypes can be influenced by 
treatment, analyzing phenotypes across different locales can provide 
insights into geographic medical practice variation. 
 
 
3.3 High-Level Tasks 
We synthesize the identified cross-sectional cohort analysis tasks to 
common visualization tasks using Brehmer & Munzner’s multi-level 
typology [3]. All tasks fall under the discover branch of why tasks are 
performed. Geneticists engage in a variety of search and query sub-
classifications, as described below: 
Explore → Summarize 
emergent patterns (W1), disease prevalence (W5), 
disease characterization (W6), 
comparison of patterns across disease subtypes (B1) 
Locate → Identify 
outlier patients/phenotypes (W2), subcohort discovery (W3), 
inform clinical practice (B3) 
Browse → Compare 
audit data quality (W4), validate data quality (B2) 
4 DESIGN PROCESS 
Having identified the common tasks of genetics researchers, we 
engaged two of the researchers in an iterative design process to 
evaluate the appropriateness of visual representations and to ensure 
the designs complemented their existing research workflows and 
mental models. We focused on analysis goals that aligned to 
exploratory tasks, rather than the application of research outcomes: 
summarizing patterns within and between cohorts (W1, B1), 
identifying outliers and subcohorts (W2, W3), and auditing and 
validating data quality (W4, B2). Each researcher provided us with a 
sample dataset of phenotype terms for 20-30 patients, which was 
representative of the size of cohorts they typically investigate. 
4.1 Phenotype Distribution and Frequency 
To support Explore → Summarize, we wanted to emphasize both the 
distribution of phenotype observations for each patent, as well as the 
frequency of each observation for each phenotype. We informed our 
design choices by eliciting feedback from researchers through a series 
of static paper-based prototypes. We considered variations using 
histograms, dot plots, scatterplots, and matrices to summarize and 
encode the distribution of phenotypes across patients and between 
cohorts. The researchers agreed that the histogram view provided a 
good summary, especially when comparing the silhouettes of 
phenotype observations between cohorts, but did not like that the 
association of observations to specific patients was obfuscated. The 
researchers preferred the matrix layout for looking at phenotype 
observations of patients, in particular a design variation that displayed 
phenotypes as rows, patients as columns, and encoded phenotype 
observations using colored cells. As matrices are often used to 
summarize results of genetics research, the researchers were familiar 
with this representation. However, this familiarity also led to 
confusion, since the use of colored cells resembled gene association 
heatmaps. One researcher commented it was awkward to see different 
data represented in this format, “I know it’s right, but it looks wrong.” 
Based on this feedback, we refined the visual appearance of the 
matrix to de-emphasize cells and encoded values using row- and 
column-aligned glyphs. We integrated histogram summaries adjacent 
to each row to facilitate frequency comparisons. We call this view an 
observations plot (Fig. 1D). To compare two cohorts, two 
observations plots are juxtaposed and the histograms are re-aligned to 
a common baseline to facilitate comparisons using the silhouette. The 
result is visually similar to existing tools (e.g., UpSet [23]) which were 
also designed to facilitate visual summaries and comparisons.    
4.2 Summarizing Phenotype Patterns 
Locate → Identify was addressed by automatically computing metrics 
of phenotype observations within a cohort and between cohorts. We 
first asked researchers to describe the patterns they typically care 
about. Within cohorts, researchers focus on whether phenotypes are 
frequently present or absent, but they are also interested in which 
phenotypes do not occur often, as these may indicate outliers. They 
also evaluate the homogeneity of phenotype observations across 
patients (i.e., are all observations present, or is there a mix?). Between 
cohorts they identify similarities and differences, as well as outliers 
and homogeneity. The researchers noted that they often have difficulty 
generating accurate summaries of their data due to the variability in 
their phenotype reports. In particular, although specific terms may be 
used (e.g., that differentiate the severity of a phenotype), they are more 
interested in whether the phenotype is present in any form. 
Aggregating patterns from granular to general phenotypes based 
on parent-child relationships of the HPO is an ideal application of the 
ontological structure. To support the variety of patterns the researchers 
requested, we automatically calculate all metrics across the cohort 
data and enable the user to select which ones are displayed. These 
summary charts can be used to identify starting points for deeper 
exploration of the details of the data (Fig. 1A). A similar approach for 
seeding exploration appeared in CoCo [25], although their summary 
metrics were not presented visually. Details of the metric calculations 
are described in Section 5.4. 
4.3 Sorting, Filtering, and Search 
To facilitate Browse → Compare, sorting and filtering operations are 
supported in the observations plot. This enables free-form exploration 
of patterns in data, similar to Bertin Matrices [29]. Sorting by 
phenotype or patient attributes reveals patterns in the observations 
plot, while filtering hides less important information from the view. 
Although none of the tasks elicited from our formative interviews 
explicitly addressed Lookup, to fill the gap in the design space, 
PhenoStacks also supports text-based search for specific phenotypes 
using natural language queries (Fig. 1E). 
4.4 Phenotype Context and Relationships 
PhenoBlocks [11] demonstrated benefits to representing phenotypes 
within the context of the semantic structure of the HPO. In terms of 
the task typology, representing phenotype relationships could improve 
Explore → Summarize, Locate → Identify, and Browse → Compare 
by adding categorical groupings to the observations plot. Thus, a key 
research question is whether this structure is also helpful within 
genetics research usage scenarios. While the researchers we engaged 
during the design process were not familiar with the HPO, hierarchical 
clustering is commonly used to add structure to results of genetic tests, 
using dendrograms to communicate clusters next to a matrix heatmap 
of test results. Inspired by these charts, and a recent evaluation 
suggesting that indented lists are more efficient at supporting 
information searches [8], we prototyped a layout view that displays the 
HPO hierarchy as a top-aligned dendrogram next to the observations 
plot, grouping related phenotype rows (Fig. 6A). Since the HPO is a 
directed acyclic graph with multiple inheritance, we converted it to a 
strict hierarchy by duplicating nodes with more than one parent. While 
this correctly mapped phenotypes to rows, feedback from researchers 
indicated duplication of phenotypes was confusing because it gave the 
false impression that there were more clusters. 
Interaction was added to the HPO dendrogram, enabling individual 
nodes to be collapsed and expanded. One researcher liked having 
granular control to define a customized tree, but the other felt any 
navigation was cumbersome and detracted from exploring the actual 
data. Both agreed that general and intermediate categories were very 
useful, but that granular categories became redundant. This feedback 
led us to develop a top-level category layout (Fig. 1B) and a cluster 
layout, computed by a novel algorithm that simplifies the ontology 
topology and selects salient intermediate categories while eliminating 
duplications (see Section 5.7). This addresses the clutter and structure 
issues in ontology visualizations identified by Katifori et al. [16]. 
4.5 Lessons Learned 
Involving researchers in the design process revealed many insights 
into how they conduct their analyses. The software researchers 
typically use to view patient records is designed primarily for data 
 
 
input and queries. While basic visualizations are supported, the 
process requires considerable effort to select data rows and columns 
and checkboxes in dialog configurations. Researchers are interested in 
their data but want to spend minimal time tuning and configuring 
interfaces. To this end, we adopt an “opt-out” approach for the 
summary charts in PhenoStacks (i.e., show more information and then 
eliminate the unneeded) rather than an “opt-in” approach (i.e., start 
with a blank slate and build the needed views). 
Our overarching goal was to support flexible free-form exploration 
of phenotype data, where users can smoothly transition between a 
variety of tasks. We quickly determined that supporting all desired 
views could not be easily merged into a single visual that would work 
in all cases. Thus, instead we opted for a range of views on the data 
that could be integrated in different ways to answer specific questions. 
5 PHENOSTACKS TOOL DESCRIPTION 
PhenoStacks is a visual analysis tool that complements the existing 
workflows of genetics researchers, and was developed based on 
feedback from domain experts. The tool supports the higher-level 
tasks researchers engage in when analyzing cohort data: summarize, 
identify, and compare [3]. PhenoStacks can be used to analyze a single 
cohort or compare two cohorts and could help with data collection 
planning and auditing, identifying potential patterns in cohort data, 
and guiding the direction of in-depth analyses. 
PhenoStacks was implemented using D3 [2], Python, and libraries 
such as SciPy to compute hierarchical clustering. In this section, we 
describe the data model, the user interface design, and how the design 
goals and user tasks are addressed through different aspects of the tool. 
5.1 Data Preparation 
Our data model is based on the notion of a cohort subgraph, a 
subgraph of the HPO that represents the cohort phenotype terms as 
leaf nodes and includes all parent nodes in a traversal to the root term 
(Fig. 2). The cohort subgraph contains the union of all phenotypes 
across all patients in the cohort, not only phenotypes thought to be 
associated with a given disease. Each node is labeled with present or 
absent for the phenotype observation of each patient in the cohort. 
Since the HPO describes “is-a” relationships between phenotypes, 
observations can be inferred for unlabeled nodes (i.e., if a phenotype 
is present, so are all ancestors; if absent, so are all descendants). Using 
these rules, unlabeled nodes are labeled with present or absent. Any 
remaining unlabeled nodes are then marked as unknown. 
Since only the labels of leaf nodes in the observations plot are 
presented, an unknown observation may obscure an observation for a 
related, but more general, phenotype. This consideration is important 
because patient phenotype reports vary widely in granularity. Thus, 
PhenoStacks checks whether any unknown nodes have observations 
associated with ancestor phenotypes (i.e., an observation for a more 
general term) and labels them present-ancestor or absent-ancestor. 
Note that these observations come from the raw data and not the 
inferred labels because all unknown nodes would then be labeled as 
they all inherit from the root (Fig. 3). 
5.2 Information Content 
One calculation enabled by the HPO and its external resources is 
information content [19], a dimensionless quantification of the 
concept of diagnostic significance. The information content for a 
phenotype is higher when its occurrence is associated with fewer 
diseases and lower when it is more common. Thus, phenotypes with 
higher information content are more likely to be useful when 
discriminating between diseases. Information content is calculated 
across a given HPO instance and is independent of the specific 
phenotypes and patients under investigation.  
5.3 User Interface 
The PhenoStacks interface comprises three distinct panels that enable 
a user to visualize and explore the cohort subgraph from overview to 
detail: a Summary Panel, a Details Panel, and a Search Panel. Each 
panel shows a different perspective on the topology of the cohort 
subgraph and supports different observations. 
The Summary Panel displays a variety of summary charts that 
display metrics of phenotype patterns across patients of a single cohort 
or between two patient cohorts (Fig. 1A). These metrics are presented 
within the hierarchical context of the cohort subgraph topology. 
Space-filling radial hierarchies were selected for the summary charts 
because they compactly encode values and equalize the size of both 
intermediate and leaf nodes. Visual emphasis on leaf nodes is critical 
because they are the most granular HPO terms. Similar charts were 
successfully used in PhenoBlocks [11]. The width of segments 
communicates the number of leaf nodes, with each leaf having equal 
weight, and all charts are sorted identically to support comparisons. 
The Details Panel consists of a layout view (Fig. 1B), a phenotype 
list view (Fig. 1C), and an observations plot (Fig. 1D) that support the 
detailed comparison of the distribution of phenotypes across patients 
and between cohorts. The layout view enables the user to control HPO 
context by selecting different methods of collapsing, filtering, and 
clustering phenotypes based on the cohort subgraph topology. The 
phenotypes list view enables phenotype terms to be sorted. The 
observations plot is a matrix of the actual and inferred phenotype 
observations for each patient in a cohort. The frequency of each 
phenotype observation is summarized in an adjacent histogram. When 
two cohorts are compared, the histograms are arranged as a silhouette 
plot between the matrix of each cohort. 
The Search Panel supports specific queries, including Boolean 
logic, to search for phenotypes by name or HPO ID (Fig. 1E). The 
search result set is persistently displayed below and matching results 
are highlighted in the Summary and Details Panels. Clicking on any 
phenotype label automatically enters the term into the search panel. 
Since PhenoStacks supports fully linked and coordinated views, 
phenotypes, patients, and observations highlight in all charts, and 
display detailed information when hovered in any of the views.  
5.4 Summarizing Patterns 
The Summary Panel presents a variety of metrics in summary charts, 
explicitly encoded with color using a divergent yellow-purple scale, 
interpolated in Lab space. These metrics are further weighted by the 
information content score of each phenotype. Users can control the 
balance between metric and information content score, whether they 
are more interested in the metric ranking alone or highly ranked 
phenotypes with high diagnostic significance. 
Fig. 2. Illustration of phenotype data translation to cohort subgraph 
representation via the topology of the HPO. Cohort subgraphs contain 
only HPO nodes for recorded patient phenotype observations. HPO 
nodes in the cohort subgraph are annotated with a list of associated 
patient phenotype observations. 
 
Fig. 3. (A) Cohort subgraph nodes are labeled using patient phenotype 
observations. (B) Labels for nodes without observations are inferred 
using HPO inheritance (1) and descendants reflect observations of 
ancestors (2). Remaining unlabeled nodes are labeled “unknown” (3). 
 
 
For within-cohort scenarios, metrics of interests are: frequently 
present/absent, infrequently present/absent, potential outliers, and 
entropy to represent homogeneity. For between-cohort scenarios, 
these metrics are: similarly present/absent, differently present/absent, 
outliers, and entropy. The outlier metric is highest for phenotypes with 
very few present or absent observations. Entropy is calculated using 
the Shannon entropy equation between present, absent, and unknown 
observations. 
These metrics are aggregated up the hierarchy and are designed to 
orient users towards phenotypes that align with the metrics in a general 
fashion; the summary charts are not designed to be carefully explored 
by users. A list of phenotypes ranked by the metric is displayed 
adjacent to each chart to highlight specifics. 
These views are designed to address first contact with the dataset. 
“What are high level features I may be interested in?” For example, 
these views can quickly give a sense of the homogeneity of the cohort, 
or the similarity between two cohorts, at a single glance (Fig. 4). 
In addition to locate, the summary charts also support lookup 
searches to starting points of potential interest. These use the 
principles of encode, aggregate, and navigate [3]. This addresses the 
issue of “Where do I start looking?” For example, phenotypes with 
high frequency can be identified, as well as outliers. 
5.5 Exploring Patterns 
The Detail Panel can be sorted across phenotypes and across patients 
to identify patterns in the observations plot. Phenotypes can be sorted 
alphabetically, by information content, by frequency, and by co-
occurrence. Patients can be sorted by ID, dataset-specific patient 
attributes (e.g. age, severity, diagnostic test scores, treatments), 
frequency, and by co-occurrence. This supports the explore task using 
the encode and navigate principles [3]. 
Frequency is calculated by counting the number of present and 
absent glyphs in each column or row, for patients and phenotypes, 
respectively. The sort order is determined first by present count, then 
by absent count, then by information content. Several methods were 
explored, but based on researchers’ feedback, this was the most 
intuitive sorting that accounted for both presence and absence. 
Co-occurrence sort order is calculated based on the results of 
hierarchical clustering. To accomplish this, observations are labeled 
(present: 1, unknown: 0, absent: -1) and a Euclidean distance metric 
was used. Determining precise clusters would require user input and 
familiarity with the clustering technique to verify and refine the 
results. To simplify the user experience, the ordering of phenotypes or 
patients from the resulting clustering output is extracted. Functionally, 
this achieves a sort order that groups similar phenotypes or patients 
next to each other, while mitigating the need for precise refinement of 
the clustering results (Fig. 5). For the purposes of an exploratory tool, 
this provides a quick and flexible estimate of potential clusters which 
can be more robustly evaluated in later analyses. 
Phenotype observations are encoded using circular glyphs. Color 
encodes the type of observation: present as purple, absent as blue, and 
unknown as light grey. Present-ancestor and absent-ancestor 
observations are represented as outlined glyphs, using the same color 
as present or absent to indicate the same class of observation (Fig. 8). 
Present and absent observations are important to differentiate, since 
present phenotypes gain diagnostic significance as they become more 
granular, while absent phenotypes gain diagnostic significance as they 
become more general. 
Phenotype information content and patient attributes are encoded 
using a monochrome scale, so as not to overpower the visualization 
with additional colors. Patient attribute values can be categorical or 
numeric. The logical ordering of categorical values along the scale can 
be dynamically defined and customized for a given dataset. Ratio 
values are binned into quantiles prior to display and the number of 
quantiles can also be dynamically selected. In both cases, attribute 
values are mapped to perceptually equidistant shades of grey. 
To reduce the number of text labels, and to support quicker 
identification, the layout views adopt the set of HPO category icons 
developed in PhenoBlocks [11]. 
5.6 Finding Specifics 
A global search enables specific phenotypes to be located by name or 
HPO ID. Search results are persistently listed below the search input 
to encourage broader search queries to find groups of phenotypes (e.g., 
searching for “musc” will return a range of muscle/muscular terms). 
Matches are highlighted in the phenotype list and summary views. 
5.7 Ontology Topology Simplification 
The layout view enables the selection of different levels of context 
based on the topology of the HPO. The initial view shows no structure, 
displaying a flat list of all phenotypes. The user can choose to add 
grouping to the phenotype terms through a category layout, which uses 
the first level HPO terms to group phenotypes at the systems-level 
(e.g., skeletal, muscular, nervous). Alternately, a tree layout supports 
free-form collapsing/expanding control to explore the entire HPO 
hierarchy. Adding grouping through the layout view engages browse 
through encode and arrange principles [3]. 
Due to multiple inheritance in the HPO, the more the hierarchy is 
expanded, the greater the complexity and visual redundancy displayed 
in the observations plot, since by default we duplicate phenotypes that 
fall under multiple categories (Fig. 6A). To balance the goals of 
increasing detail while minimizing complexity, a novel algorithm was 
developed to simplify the topology of the HPO. At a high-level, the 
algorithm eliminates multiple inheritance by extracting a single path 
from the root to each leaf phenotype, based on an evaluation of the 
Fig. 4. Each summary chart encodes a specific metric (e.g., frequency, 
similarity, entropy, outliers), weighted by the diagnostic significance 
score. (A) Darker colors indicate stronger metrics, e.g., two cohorts 
share important phenotypes, while (B) lighter colors show weaker 
scores, e.g., two cohorts lack diagnostically significant differences. (C) 
Ancestor nodes aggregate the metrics of children, e.g., a darker purple 
parent indicates this general term appears in all patients. 
Fig. 5. Observations can be sorted by phenotypes and/or patients 
(e.g., co-occurrence, frequency, patient attributes) to reveal patterns. 
Fig. 6. Example representations of the HPO topology in the layout view. 
(A) The tree layout can be manually expanded and collapsed, but 
results in phenotype duplication due to multiple inheritance. (B) The 
cluster layout categorizes phenotypes using our topology simplification 
algorithm eliminating duplications. A phenotype is highlighted in yellow. 
 
 
information content of intermediate phenotypes. Phenotypes that do 
not contribute to the grouping are then removed (i.e., parents with only 
a single child). Conceptually, the result is a detailed and diagnostically 
significant categorization for each phenotype that minimizes 
complexity (Fig. 6B). The algorithm is as follows (Fig. 7): 
1. For each leaf in the cohort subgraph, create a leaf subgraph containing 
all paths back to the root. 
2. For each leaf subgraph, use a greedy depth-first approach to extract 
the path from root to leaf that passes through the child with the highest 
information content at each depth. If more than one path is found, 
select the path with the highest cumulative information content. 
3. Merge all extracted leaf paths into a new cluster tree. 
4. Traverse the cluster tree depth-first and remove nodes with only one 
child, stopping when a node has more than one child, and ensuring 
leaf nodes have at least one parent. Remove the root node. 
The fourth step of the algorithm results in a cluster tree that 
contains all leaf nodes, without duplications, grouped using 
diagnostically significant intermediate phenotype categories. Since 
this method is based on the topology of the HPO and information 
content score, it is independent of the data being displayed. However, 
depending on the phenotypes exhibited by patients in a cohort, 
categories may be more or less specific; disparate phenotypes will be 
categorized more granularly, while related phenotypes will be 
clustered together under more general categorizations.  
This method requires more robust evaluation, and does not 
currently support user intervention. For example, a parameter could 
be introduced to control the aggressiveness of intermediate phenotype 
removal (Step 4), to control the granularity of computed categories. In 
terms of our goals in this work, the implementation was sufficient to 
evaluate whether we could compute an intuitive simplified topology 
using the concept of diagnostic significance. 
6 EXPERT EVALUATIONS 
To evaluate PhenoStacks, we deployed the tool in the labs of four 
experienced genetics researchers. All four participated in the 
formative interviews, but only one participated in the iterative design 
process. We asked each researcher to provide a cross-sectional cohort 
dataset they were studying, or had previously analyzed, as well as 
patient attributes they were interested in evaluating. Semi-structured 
interviews were conducted to learn more about each disease and the 
particular aspects of the cohorts that they were interested in exploring.  
The phenotype data was provided in text format and translated to 
HPO terms using a dictionary mapping approach; the mapping schema 
was verified by the researchers. We introduced PhenoStacks with their 
data, explained the visual encoding, and demonstrated the interface to 
each researcher and their associates. The deployment period lasted 3-
7 days, depending on availability. Researchers were instructed to use 
the tool for at least 1 hour over this period and encouraged to engage 
research associates in these explorations. Deployment periods ended 
with semi-structured interviews, asking participants to demonstrate 
insights garnered using PhenoStacks and to reflect on its utility as part 
of their workflow. HPO layouts were ranked to evaluate the output of 
our simplification algorithm, and we elicited general feedback and 
suggestions for improvements. All participants confirmed they had 
used the tool independently, as well as with members of their research 
teams, for a total of 1-2 hours each over the deployment period. 
6.1 Usage Scenario Case Studies 
First, we summarize descriptions of each disease and how the tool was 
used by the researchers for their specific tasks. 
6.1.1 Inflammatory Bowel Disease 
Inflammatory Bowel Disease (IBD) describes a range of genetic 
disorders that affect the gastrointestinal (GI) system. Patients display 
widely heterogeneous symptoms due to multi-factorial causes (e.g., 
genetics, lifestyle, environment) which makes investigating the 
disease challenging.  The IBD researcher was interested in comparing 
patients with early onset IBD against patients who develop the disease 
later in life. This task aligns to finding patterns between cohorts (B1), 
with the goal of differentiating congenital and adult onset forms of the 
disease. He provided two between-cohort datasets that focused on 
patients with severe presentations of the disease. The first compared 
17 and 6 patients, while the second compared 28 and 19 patients. 
We conducted evaluation interviews with two research associates 
because the researcher was unavailable. While transcribing the data to 
HPO terms, it became clear that the granularity of terms involved in 
IBD were not yet sufficiently defined in the HPO. This presents an 
opportunity to contribute modifications to the HPO to expand their 
coverage for this disease. However, the potential of using standardized 
and structured phenotype data was immediately clear. “I can see a 
tremendous amount of utility for the tool… it really makes patterns 
clear,” one commented. “Being able to show this is where you have 
commonality and this is where you start seeing differences. That 
would be powerful in and of itself; even before you reach the 
functional and translational implications.” They were also excited 
about the potential to compare cohort data along other vectors, such 
as geographic location, to assess potential environmental factors. 
This discussion echoed a common pain point for researchers 
regarding data collection, which often aligns with clinician-patient 
interactions, but is less suited to research goals. The phenotyping is 
very broad, less systematic, and detail is not consistent. Investing in 
standardized data collection methods and developing guidelines to 
improve consistency would facilitate researcher collaborations, within 
and between institutions. The difficulty lies in reaching consensus 
regarding data collection granularity with the clinicians who actually 
record the data. The researchers felt PhenoStacks would be a compel-
ling artifact to communicate the benefits and to ground discussion. 
6.1.2 Myotonic Dystrophy 
Myotonic dystrophy is a hereditary multi-systemic disease character-
ized by progressive degeneration of muscle that weakens the 
musculoskeletal system, affects cardiovascular function, and results in 
endocrine changes. The researcher we interviewed wanted to evaluate 
patterns within a single cohort of 40 patients. In particular, he wanted 
to identify similarities in the cohort (W1) and look for subcohorts 
(W3) based on attributes of the patients, such as age and a potential 
measure of disease severity. He indicated that finding biochemical 
metrics that consistently correlate with aspects of the disease, such as 
severity, are critical to selecting appropriate treatments for patients. 
The researcher appreciated sorting patients and phenotypes by co-
occurrence. “I can see very nice clusters of [phenotypes] coming 
together, which really make sense knowing the disease well.” He 
commented the summary charts complemented the observations plot. 
By seeing the overall patterns, he was guided to confirm where the 
numbers were coming from. Sorting the patients by the potential 
severity metric clearly revealed a progression to more severe patient 
cases, noted by an increased presentation of severe phenotypes, 
suggesting the metric may indeed be a valid measure of disease 
severity (Fig. 8). Moreover, sorting by age could help to investigate a 
suspected inflection point, where the congenital version of the disease 
transitions into the more typical, adult degenerative version.  
While he did not state it as one of his primary tasks, the researcher 
commented that outliers were very easy to spot (W2). He identified 
two examples of severe cases that stood out, due to the severity of the 
phenotypes, guided by hotspots in the outlier summary chart. 
Fig. 7. Illustration of our ontology simplification algorithm. 
 
 
Exposure to the HPO raised questions about the correctness and 
completeness of his data. While common phenotypes were clear, he 
had hoped to see more differentiation along severe symptoms. He 
identified several phenotypes that he felt could be recorded at higher 
granularity to better capture subtle variations between patients (W4). 
This suggests that PhenoStacks could be used to audit data collection 
and help in data collection planning by identifying where deeper 
phenotyping could better differentiate subcohorts of patients.  
6.1.3 Myotubular Myopathy 
Myotubular myopathy is a congenital neuromuscular disease marked 
by abnormal skeletal muscle fiber cells with diminished function, 
resulting in muscle weakness in patients. Patients present with a 
variety of phenotypes and researchers are still trying to better 
understand the genetic causes and differentiate subclasses of the 
disease. The researcher we interviewed was conducting a study to 
compare phenotypes of a new patient cohort to those of existing 
published case reports in the literature (B2). The cohorts contained 12 
and 10 patients. He was particularly interested in the similarities and 
specific differences between the two cohorts. 
He commented that overall the tool was very useful for his research 
goals. Visually comparing the similarities and differences using the 
observations plot was far easier than the spreadsheet-based approach 
he was using before. The grouping of phenotypes based on the cluster 
layout helped to merge cases where different terms were used to 
describe similar clinical features. “In the [case study] cohort, we saw 
a lot of ‘Respiratory insufficiency due to muscle weakness’ and we 
thought: no one in our cohort has that, but then you go down to 
‘Respiratory failure requiring ventilation’—these are basically the 
same thing—and then the data looks more comparable.”  
The researcher also stated that in general, the tool would be 
especially useful when collecting new data. The new data could be 
quickly compared to the existing cohort and evaluated to see if the 
new data was robust enough (i.e., complete, granular, and consistent 
with other patients). This maps to the data auditing task (W4) we 
identified in our formative interviews, but did not originate from 
discussions with this researcher. 
6.1.4 Phenylketonuria 
Phenylketonuria (PKU) is a congenital disease resulting in impaired 
metabolism of the amino acid phenylalanine. Untreated, the disease 
affects the neurological system, leading to intellectual disabilities and 
other severe medical problems. The researcher we interviewed is also 
a clinician and was interested in the variation of phenotypes within a 
cohort of his clinical patients to identify cases where the treatment 
regimen has not been effective. Thus, this use case was more oriented 
towards clinical diagnostics. He provided us with phenotype data for 
12 random patients. Several attributes were provided for each patient, 
including metrics of disease management and severity. 
During the interview, he first demonstrated how the observations 
plot revealed patterns he expected to see. For example, when sorting 
by increasing severity: “It’s nice to see it work, with neurological 
features appearing [in more severe cases].” He commented that the 
“frequently present” summary chart was very useful for diagnostic 
purposes, since darker colors immediately indicated something he 
should investigate. He also commented that the visualization could be 
used to identify groups of patients within the cohort (W3), for example 
patients who are not managing their disease effectively. 
He also used the tool to explain hypotheses about why the 
treatment regimen was not meeting the needs of certain patients. For 
example, if all patients had the disease under control, the measure of 
management should be roughly equivalent, but sorting by severity 
indicated that the management score was worse for certain severe 
cases. These are cases where the current treatment is not working and 
the treatment should be reassessed. “[PhenoStacks] provides me with 
a nice visualization for management... to see where we are in meeting 
our expectations. I know what I should be seeing, and when I’m not 
seeing it, it’s informative.” 
6.2 General Feedback 
Having described detailed usage scenarios and comments from the 
researchers, we now address higher-level shared feedback. 
6.2.1 HPO Layout Methods 
The cluster layout method (using our simplification algorithm), was 
the preferred layout (2/3 researchers and both research associates), 
followed by the flat view. These participants were all focused on 
research-oriented use cases, where they were either interested in 
seeing global co-occurrences, or investigating particular sub-systems, 
which was easier to do with the clusters layout; the category layout 
was too broad, and the tree layout had too many duplications. One 
researcher commented that for his data, the clusters were sometimes 
too specific, and he would like some control to “relax” the output so 
that more general categories would be selected. While category 
granularity preference differed by researcher, these results indicate 
that computational approaches to simplifying the HPO topology is a 
promising direction to aid contextualization of phenotype data.  
The PKU researcher preferred the tree layout, and then the cluster 
view. He explained that for his purposes (i.e., clinical diagnostics), he 
was more interested in specific phenotypes, and less about how they 
relate to each other. In fact, while the structure of the HPO made sense 
to him, it was contrary to his mental model of diagnosis, which started 
with detailed presentations, not categories. His preferences thus 
aligned with the layouts that showed the most detailed view. This 
suggests that representing phenotypes in the context of the HPO may 
be less critical when designing visualizations for clinical diagnostics. 
Overall, we received positive feedback on the algorithm to cluster 
phenotypes to eliminate duplications. The IBD research associates 
especially liked that it not only removed duplicates, but also presented 
phenotypes in categories that made the most sense. “Cholangitis is a 
co-presenting liver abnormality, while it is also related to immune 
system, this isn’t how we think about it. The cluster view groups the 
two liver phenotypes together, separating it from the GI phenotypes. 
This makes sense and it’s helpful to see that separation.” (Fig. 9) 
6.2.2 Data Quality Concerns 
We worked with the researchers to map the phenotype terminology 
and clinical results of their data to the HPO. For the most part this was 
straight-forward, but as we described for IBD, sometimes HPO terms 
were missing. Since the HPO is an ongoing project, engaging 
researchers across a wider variety of diseases is an opportunity to 
benefit from their expertise to help improve the HPO. 
During the process, the benefits of the structured phenotype data 
became clear to all participants. Ambiguities in the description of 
phenotypes in the researchers’ datasets were uncovered, making it 
unclear what HPO term was appropriate, echoing issues reported in 
the literature. In these cases, a more general HPO term was used, but 
for the researchers this underscored the benefits of integrating the 
HPO into the data collection process at the beginning. By visualizing 
phenotypes using the HPO, deeper phenotyping benefits also became 
clear, because the researchers could see areas where they were not 
Fig. 8. An example observations plot from the myotonic dystrophy 
dataset. Sorting patients by severity reveals a pattern of increasing 
present observations (purple) of more severe phenotypes (lower in the 
chart) as we move from less to more severe patient cases (to the right). 
 
 
seeing the differentiation they expected because the phenotypes in 
their data were too general. The researchers also noted that if their 
collaborators were also using the HPO, it would make it easier to 
merge datasets, even if they are recorded at different granularities, 
because the topology of the HPO accommodates these differences. 
Thus, these observations suggest that visualizations can help 
communicate the benefits of structured phenotype data in supporting 
consistency, completeness, and granularity. 
6.2.3 Sharing and Collaboration 
All researchers commented that the visualization would be good for 
communicating with collaborators and presenting and sharing results. 
The different layout views were seen as useful for projects involving 
collaborators with different levels of expertise, for example geneticists 
who are less familiar with specific phenotypes and more focused on 
the systems-level. Seeing the categories would help bridge knowledge 
gaps with unfamiliar terms by showing how they relate to each other. 
The observations plot was also seen as a valuable aid when 
discussing and communicating insights. Being able to see the patterns 
and show them to other researchers was seen as far better than simply 
sharing the information using text descriptions. For example, the 
categorizations using the HPO topology clearly delineate related 
phenotypes and also indicate specific subsystems that may play a role 
in the disease, helping to differentiate localized and systemic 
symptoms. To compare results, researchers could ask collaborators to 
describe the pattern of symptoms they are seeing within a certain 
category, rather than simply sharing specific phenotypes. This can also 
support collaboration between experts with different specializations. 
6.2.4 Suggested Improvements 
The researchers were eager to share ideas to improve the tool. The 
PKU and myotonic dystrophy researchers, who considered the task of 
subcohort discovery (W3), suggested additional features to organize 
patients in the observations plot. For example, one suggested visually 
separating patients into distinct subgroups within each cohort. Both 
researchers wanted to collapse subgroups into a single column to hide 
patients that were less important to the analysis at hand. They also 
both wanted to add ad hoc attributes to the patients dynamically during 
analysis, to impose custom sort orders on the patients. This desire for 
greater interactive control over patient organization suggests that 
participants were embracing interactive visual analysis as part of their 
workflows, and could envision more advanced features. 
The IBD research associates suggested labeling certain phenotypes 
“very important”, so that the frequency scores of these would be 
highlighted, regardless of their diagnostic significance, “If you know 
you’re interested in certain phenotypes, it would be nice to see them 
immediately.” While the information content does map to diagnostic 
significance, in some cases they were interested in the presentation of 
phenotypes that were more common, but very significant when they 
co-present with other phenotypes in IBDs. 
In a similar vein, the myotonic dystrophy researcher wanted to add 
attributes to the phenotypes, similar to the patient attributes, that could 
be used to sort the phenotypes list differently. In particular, a measure 
of frequency within the disease or a correlation with severity was 
desired, as this would impose unique clustering when paired with co-
occurrence in patients. 
Finally, all the researchers and research associates wanted a 
longitudinal version of this tool, since there were aspects of their 
patients that they wanted to visually track over time. 
6.3 Study Limitations 
This study is not without its limitations. The deployment period was 
short and variability of phenotype coverage in the HPO impacted the 
depth of some data explorations. However, we engaged researchers 
across a variety of specializations and garnered insightful feedback. 
The researchers were exposed to structured phenotype data and gained 
increased sensitivity to the quality of their own data. 
A long-term deployment study of PhenoStacks is being planned. 
Working with a researcher and his team, we are submitting updates to 
the HPO so that the phenotypes are well represented. PhenoStacks will 
be deployed among a large group of researchers participating in a data 
collection workshop to support data auditing and analyses thereafter.   
7 CONCLUSION AND FUTURE WORK 
This work introduced PhenoStacks, a visual analysis tool to support 
cross-sectional cohort phenotype analyses. A novel algorithm was 
developed to simplify the visual display of the HPO topology and 
eliminate duplicated terms. Based on feedback from expert genetics 
researchers, this algorithm and the layouts that were produced were 
preferred over category and tree layouts. Deployment study results 
indicated many potential applications within the researchers’ existing 
workflows. These visualization concepts can be applied in other 
domains where instances of taxonomies or ontologies are analyzed. 
The deployment study identified several improvements that we 
plan to address in subsequent open-source releases. Agglomerating 
patient columns would benefit analyses, but also address scalability to 
larger cohorts. Methods of collapsing the HPO topology (e.g., fish-eye 
distortion) could further mitigate clutter when cohorts contain a wide 
variety of phenotypes. Both approaches could integrate user-authored 
tags (e.g., important phenotypes) and ad hoc attribute definition. 
Given a richer range of attributes, alternate visualizations of attributes 
are worth investigating (e.g., scatterplots to evaluate correlations). 
Based on feedback, we plan to extend PhenoStacks to longitudinal 
cohort analyses. While clinical studies consider sequences of temporal 
events (e.g., hospital visits, treatments), genetics researchers focus on 
how phenotypes of a patient change over time. These natural history 
studies track disease progression in cohorts, e.g., investigating the 
effect of environmental exposures or lifestyle on the manifestation of 
phenotypes. We see promise in applying approaches, such as temporal 
metrics (as in CoCo [25]), to longitudinal phenotype analyses. 
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Fig. 9. Comparison between category and cluster layouts. Cholangitis, 
an inflammation of the liver, (A) appears under both Immune System 
and Abdomen in the category view, where it is grouped with mostly 
gastrointestinal abnormalities. (B) The cluster layout selects a more 
meaningful organization that separates Gastrointestinal abnormalities 
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